Tiziana Life Sciences plans to assess intranasal foralumab for long Covid
Pharmaceutical Technology
APRIL 14, 2023
Biotechnology company Tiziana Life Sciences has revealed plans to assess intranasal foralumab as a potential treatment for long Covid. Long Covid is a health condition characterised by the continuation or development of new symptoms three months after an initial SARS-CoV-2 infection.
Let's personalize your content